OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Tasadenoturev active in DIPG	1190
A new standard of care for advanced-stage urothelial carcinoma	857
From little subclones grow mighty oaks	811
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	802
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	764
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	728
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	692
Novel ICI–TKI combination improves HCC outcomes	680
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	596
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	589
Hodgkin lymphoma: great progress with room for improvement	585
Ecological management of the microbiota in patients with cancer	582
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	561
The emerging roles of circRNAs in cancer and oncology	496
Current understanding and management of CAR T cell-associated toxicities	496
Gut microbiota in colorectal cancer development and therapy	495
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	432
From ESMO 2022	429
From the ESMO Congress 2021	417
Mortality is similar with active monitoring	402
Contrasting results with second-line CAR T cells in large B cell lymphoma	353
Ponatinib superior to imatinib in Ph+ ALL	348
Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?	344
Sacituzumab tirumotecan improves OS in mTNBC	343
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	339

Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	316
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	307
Understanding and overcoming multidrug resistance in cancer	293
Humanized mouse models for immuno-oncology research	259
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	255
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	254
Harnessing cytokines and chemokines for cancer therapy	243
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	237
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	228
Craniospinal irradiation improves leptomeningeal metastasis control	225
Survival benefit with second-line combination in endometrial cancer	223
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	222
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	222
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	218
Spatial landscapes of cancers: insights and opportunities	218
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	216
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	211
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	207
Harnessing big data to characterize immune-related adverse events	196
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	189
Improving outcomes in patients with oesophageal cancer	183
Biomarkers for immunotherapy of hepatocellular carcinoma	181
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	179
New CAPSTONE of SCLC therapy?	174
SHINE a light: frontline ibrutinib for MCL	170
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions	170
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	163
Women with clinically node negative breast cancer can safely avoid axillary surgery	162
Aumolertinib is effective in NSCLC	156
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond	156
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	154
From ESMO 2023: advances in lung cancer	153
DREAMseq of therapy for BRAF-mutant melanoma	144
Prospective comparisons support the use of navigational bronchoscopy	142
Targeting chromosomal instability in patients with cancer	142
Circulating tumour DNA — looking beyond the blood	134
Long-term outcomes following CAR T cell therapy: what we know so far	133
Mitigating acute chemotherapy-associated adverse events in patients with cancer	128
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	125
Benefit with ramucirumab in mesothelioma	114
Response to neoadjuvant endocrine therapy complements recurrence score	114
Multiomics STEP up in correlative analysis of response to CAR T cells	113
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	110
From the ESMO Congress 2023	104
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	101
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	101
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	100
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	93
HAIC-FO improves outcomes in HCC	91
Enhancing immunotherapy with tumour-responsive nanomaterials	90

Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	90
Clinical implications of T cell exhaustion for cancer immunotherapy	89
Lung cancer in patients who have never smoked — an emerging disease	89
Newly approved cancer drugs in China — innovation and clinical benefit	89
Claudin 18.2 as a novel therapeutic target	87
Targeted biopsy reduces detection of clinically insignificant cancer	86
Combining CAR T cells effective in RRMM	84
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	83
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	80
Less-frequent surveillance is noninferior to annual mammography	80
Barriers in access to oncology drugs — a global crisis	78
T-DXd effective as second-line therapy in G/GEJ cancers	77
Second-line tarlatamab improves OS in SCLC	74
Translating biological insights into improved management of endometrial cancer	72
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	69
BrECADD raises the bar in classical Hodgkin lymphoma	68
Two decades of advances in clinical oncology — lessons learned and future directions	68
HSCT prolongs remission of high-risk CTCLs	66
Nirogacestat effective in desmoid tumours	62
Promise with co-administration of CAR T cells	61
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	60
GPRC5D-CAR T cells active in MM	57
Promising OS with oncolytic virotherapy	57
Efficacy of TILs confirmed	55
Thermal ablation is safer than resection of colorectal liver lesions	55
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	54
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	53
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	53
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	53
Exploiting bacteria for cancer immunotherapy	53
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	51
The current state of the art and future trends in RAS-targeted cancer therapies	49
Repotrectinib effective in ROS1-fusion-positive NSCLC	48
Neoadjuvant pembrolizumab improves outcomes	45
MSI-H/dMMR mCRC: ICIs in the first line?	41
LAG3 inhibition improves outcomes	40
Belzutifan is active in VHL-related cancers	40
Pembrolizumab tunes up chemotherapy in cervical cancer	40
KN046 shows tolerability and activity in TNBC	39
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	38
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	37
Problematic crossovers in cancer drug trials	37
The emerging roles of γδ T cells in cancer immunotherapy	36
Integrated MRI-guided radiotherapy — opportunities and challenges	36
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	32
CAR T cells induce durable remission of neuroblastoma	30
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	29
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	28
National value-based pricing negotiation for oncology drugs — lessons from China	27
Author Correction: EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	27
Axicabtagene effective in indolent NHL	26
GPRC5D as a novel immunotherapeutic target in multiple myeloma	25
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	25
Personalizing adjuvant therapy for patients with colorectal cancer	25
Laparoscopic TME is non-inferior	23
Epcoritamab is active in large B cell lymphomas	23